TLR7 and neoplasm: This folate receptor-targeted TLR7 agonist was chosen for reprogramming of the tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) because a related FA-TLR7 agonist conjugate had been previously shown to convert M2-like immunosuppressive myeloid cells into M1-like inflammatory myeloid cells in solid tumors (17) without directly affecting any other immune cells in the body.